SynthesisBMC cancer2026
Impact of cancer treatment on fertility in female childhood and adolescent cancer survivors: a systematic review and meta-analysis.
Synthesis in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWith the improvement of the survival rate of children with caners, increasing attention is being paid to their long-term quality of life, especially the fertility concerns of female survivors. Here, we assess the impact of cancer treatment on the fertility in female childhood and adolescent cancer survivors.
methodsTo identify relevant studies, a systematic literature search was performed in PubMed, Medline, Embase, and other databases. The search focused on treatment-related fertility impairment in pediatric or adolescent cancer patients and included cohort, case–control, and cross-sectional studies. Only articles published in Chinese or English, spanning from database inception to July 29, 2024, were retrieved. Review Manager 5.4 software was employed for the meta-analysis.
resultsFollowing screening of 945 records, 20 studies met the inclusion criteria, yielding a final cohort of 7,217 patients.The synthesis results indicated that the impaired risk of fertility in female childhood and adolescent cancer survivors was significantly increased versus the population without cancer treatment (OR: 5.55, 95% CI: 2.38–12.89, P < 0.001). The survivors with hematologic malignancies had an elevated risk of impaired fertility (OR: 3.98, 95% CI: 1.18–13.45, P < 0.05). And, the risk in the survivors was significantly higher with alkylating agent doses greater than 8000 mg/m2 (OR: 8.29, 95% CI: 3.16–21.77, P < 0.001), Ovaries within the radiation field (OR: 43.40, 95% CI: 26.08–72.22, P < 0.001), and stem cell transplantation (SCT) (OR: 16.07, 95% CI: 8.00–32.29, P < 0.001). Furthermore, the survivors who received cancer treatment after puberty had the elevated risk (OR: 1.88, 95% CI: 1.23–2.88, P < 0.001). In contrast, treatment before puberty was not associated with a significantly increased risk in this cohort.
conclusionsFor female childhood cancer patients undergoing cancer treatment, alkylating agents, ovarian exposure to radiation therapy, and SCT all elevated the impaired risk of fertility. Therefore, effective fertility preservation measures should be proactively provided to this population to mitigate the fertility damage associated with cancer treatments and protect the fertility function of female childhood cancer survivors.
trial registrationPROSPERO registration number: CRD420250655189.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.